Protagonist Q1 2022 Earnings Report
Key Takeaways
Protagonist Therapeutics reaffirmed rusfertide as the primary focus, presented topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis, and received a $25 million milestone payment from Janssen.
Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera.
Presented topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis with consistent treatment effects at the lower 150 mg BID dose across key endpoints.
Engaged PJT Partners to lead external partnering efforts for PN-943.
Received a milestone payment of $25 million from Janssen upon dosing of the third patient in the Phase 2B FRONTIER-1 study of PN-235 in psoriasis.
Protagonist
Protagonist
Forward Guidance
Protagonist expects activities related to PN-943 to have a minimal impact on cash resources and retains cash runway guidance through the end of 2024.